Pierre Aman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3105367/publications.pdf

Version: 2024-02-01

53 papers	3,571 citations	257450 24 h-index	214800 47 g-index
53 all docs	53 docs citations	53 times ranked	3849 citing authors

#	Article	IF	Citations
1	FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma. Frontiers in Oncology, 2022, 12, 816894.	2.8	7
2	FET fusion oncoproteins interact with BRD4 and SWI/SNF chromatin remodelling complex subtypes in sarcoma. Molecular Oncology, 2022, 16, 2470-2495.	4.6	12
3	Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo. Biomedicines, 2022, 10, 624.	3.2	3
4	Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma. Oncogenesis, 2022, 11, 20.	4.9	14
5	Total mRNA Quantification in Single Cells: Sarcoma Cell Heterogeneity. Cells, 2020, 9, 759.	4.1	7
6	IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors. Cells, 2019, 8, 913.	4.1	32
7	JAKâ€“STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma. International Journal of Cancer, 2019, 145, 435-449.	5.1	52
8	<scp>FET</scp> family fusion oncoproteins target the <scp>SWI</scp> / <scp>SNF</scp> chromatin remodeling complex. EMBO Reports, 2019, 20, .	4.5	52
9	Requirement for YAP1 signaling in myxoid liposarcoma. EMBO Molecular Medicine, 2019, 11, .	6.9	25
10	Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma. Molecular Cancer Therapeutics, 2019, 18, 834-844.	4.1	28
11	Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone. Scientific Reports, 2019, 9, 19704.	3.3	18
12	Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses. Laboratory Investigation, 2018, 98, 957-967.	3.7	6
13	FUSâ€“DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. Clinical Cancer Research, 2017, 23, 6227-6238.	7.0	40
14	Cell Cycle and Cell Size Dependent Gene Expression Reveals Distinct Subpopulations at Single-Cell Level. Frontiers in Genetics, 2017, 8, 1.	2.3	149
15	HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat. Journal of Pathology: Clinical Research, 2016, 2, 59-71.	3.0	9
16	Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Laboratory Investigation, 2016, 96, 885-894.	3.7	17
17	Regulatory mechanisms, expression levels and proliferation effects of the FUSâ€“DDIT3 fusion oncogene in liposarcoma. Journal of Pathology, 2016, 238, 689-699.	4.5	13
18	HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell deathin vitroandin vivo. Oncotarget, 2016, 7, 433-445.	1.8	12

#	Article	IF	Citations
19	<scp>SRC</scp> inhibition represents a potential therapeutic strategy in liposarcoma. International Journal of Cancer, 2015, 137, 2578-2588.	5.1	18
20	Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma. Cancer Letters, 2015, 367, 147-156.	7.2	9
21	Fusion Oncogenes of Sarcomas. , 2015, , 321-331.		1
22	Normal and Functional TP53 in Genetically Stable Myxoid/Round Cell Liposarcoma. PLoS ONE, 2014, 9, e113110.	2.5	19
23	Cell Senescence in Myxoid/Round Cell Liposarcoma. Sarcoma, 2014, 2014, 1-7.	1.3	11
24	DDIT3 Expression in Liposarcoma Development. Sarcoma, 2014, 2014, 1-6.	1.3	11
25	A conserved Nâ€terminal motif is required for complex formation between FUS, EWSR1, TAF15 and their oncogenic fusion proteins. FASEB Journal, 2013, 27, 4965-4974.	0.5	34
26	Fused in sarcoma (FUS) interacts with the cytolinker protein plectin: Implications for FUS subcellular localization and function. Experimental Cell Research, 2012, 318, 653-661.	2.6	9
27	Distinct Cytoplasmic and Nuclear Functions of the Stress Induced Protein DDIT3/CHOP/GADD153. PLoS ONE, 2012, 7, e33208.	2.5	87
28	Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Molecular Cancer Therapeutics, 2009, 8, 449-457.	4.1	160
29	The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biology, 2008, 9, 37.	3.0	284
30	Characterization of the 12q amplicons by high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line. Cancer Letters, 2008, 260, 37-47.	7.2	40
31	Irradiation of myxoid/round cell liposarcoma induces volume reduction and lipoma-like morphology. Acta OncolÃ³gica, 2007, 46, 838-845.	1.8	58
32	The Myxoid/Round Cell Liposarcoma Fusion Oncogene FUS-DDIT3 and the Normal DDIT3 Induce a Liposarcoma Phenotype in Transfected Human Fibrosarcoma Cells. American Journal of Pathology, 2006, 168, 1642-1653.	3.8	91
33	Fusion oncogenes in tumor development. Seminars in Cancer Biology, 2005, 15, 236-243.	9.6	31
34	Myxoid liposarcomaFUSâ€ĐDIT3fusion oncogene induces C/EBP Î²â€mediated interleukin 6 expression. International Journal of Cancer, 2005, 115, 556-560.	5.1	44
35	Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas. International Journal of Oncology, 2004, 25, 1349-55.	3.3	12
36	Temperature-Dependent Localization of TLS?CHOP to Splicing Factor Compartments. Experimental Cell Research, 2002, 278, 125-132.	2.6	20

#	Article	IF	Citations
37	The myxoid liposarcoma specificTLS-CHOPfusion protein localizes to nuclear structures distinct from PML nuclear bodies. International Journal of Cancer, 2002, 97, 446-450.	5.1	27
38	Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 439, 141-151.	2.8	101
39	Fusion genes in solid tumors. Seminars in Cancer Biology, 1999, 9, 303-318.	9.6	95
40	A novel PCR-based approach for the detection of the Huntington disease associated trinucleotide repeat expansion. , 1999, 13, 232-236.		8
41	A methylation PCR approach for detection of fragile X syndrome. , 1999, 14, 71-79.		39
42	Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas. , 1999, 83, 30-33.		64
43	The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Letters, 1997, 417, 85-88.	2.8	227
44	Variable FHIT transcripts in nonâ€neoplastic tissues. Genes Chromosomes and Cancer, 1997, 19, 215-219.	2.8	38
45	Expression Patterns of the Human Sarcoma-Associated GenesFUSandEWSand the Genomic Structure ofFUS. Genomics, 1996, 37, 1-8.	2.9	144
46	Duplication of chromosome segment 12q15-24 is associated with atypical lipomatous tumors. A report of the CHAMP collaborative study group. , 1996, 67, 632-635.		34
47	Genomic PCR detects tumor cells in peripheral blood from patients with myxoid liposarcoma. , 1996, 17, 102-107.		25
48	Cloning and sequencing of a cDNA encoding ratd-dopachrome tautomerase. FEBS Letters, 1995, 373, 203-206.	2.8	52
49	Fusion of theFUS gene withERG in acute myeloid leukemia with t(16;21)(p11;q22). Genes Chromosomes and Cancer, 1994, 11, 256-262.	2.8	116
50	The 12q13-q15 translocation breakpoints in pleomorphic adenoma and clear-cell sarcoma of tendons and aponeuroses are different from that in myxoid liposarcoma. Genes Chromosomes and Cancer, 1993, 7, 178-180.	2.8	15
51	Mapping of the 19p13 breakpoint in an ovarian carcinoma between theINSR andTCF3 Loci. Genes Chromosomes and Cancer, 1993, 8, 134-136.	2.8	8
52	Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature, 1993, 363, 640-644.	27.8	859
53	Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes and Cancer, 1992, 5, 278-285.	2.8	284